Bicara Therapeutics Inc. 8K

Bicara Therapeutics appointed Jeremy Bender and Christy Oliger to its Board of Directors and announced the retirement of founding Board member Kiran Mazumdar-Shaw.

On July 28, 2026, Bicara Therapeutics Inc. announced that it has appointed Jeremy Bender, Ph.D., MBA, former CEO of Day One Biopharmaceuticals, and Christy Oliger, a longtime Genentech executive, to its Board of Directors, bringing extensive strategic, commercial, and operational biopharmaceutical experience to support the company’s transition toward potential commercialization of its lead program, ficerafusp alfa, while simultaneously disclosing that founding Board member Kiran Mazumdar-Shaw has retired from the Board. The company emphasized that the new directors’ backgrounds in oncology product launches, corporate strategy, and late-stage portfolio management are expected to bolster Bicara’s efforts to advance registration-enabling studies and prepare for potential regulatory approval and commercialization, and expressed appreciation for Mazumdar-Shaw’s contributions, including early seed capital and strategic guidance that helped progress ficerafusp alfa into the clinic.

Filing Facts

CIK

2023658

Ticker

BCAX

Form

8K

Source Type

fda

Accession

0001628280-26-049937

Alert Tier

5